CMV pp65 Activators
The class of CMV pp65 activators includes a diverse group of chemicals that can potentially modulate the activity of CMV pp65, a phosphoprotein implicated in various cellular processes during human cytomegalovirus (CMV) infection. These activators, either directly or indirectly, impact the function of CMV pp65, contributing to the dynamic interplay between the virus and host cellular pathways. One category of CMV pp65 activators comprises inhibitors targeting key signaling pathways involved in CMV pp65 activation. Compounds such as SB203580, U0126, and LY294002 act as indirect activators by inhibiting the p38 MAP kinase, MEK/ERK, and PI3K/Akt pathways, respectively. These pathways are intricately linked to CMV pp65 function, and their inhibition can alter the phosphorylation status of CMV pp65, influencing its role in viral replication and host immune response. Additionally, inhibitors like BAY 11-7082, SP600125, and Rapamycin indirectly modulate CMV pp65 by targeting NF-κB, JNK, and mTOR pathways, respectively. These pathways play crucial roles in the regulation of CMV pp65 expression and activity, and their inhibition can potentially disrupt viral replication and host antiviral responses.
Wortmannin, SP2509, JSH-23, and BIX 01294 represent another category of CMV pp65 activators, influencing epigenetic and nuclear processes. Wortmannin, a PI3K inhibitor, impacts cellular signaling cascades linked to CMV pp65, while HDAC inhibitors like SP2509 and BIX 01294 modulate histone acetylation and methylation, respectively, potentially affecting CMV pp65 gene expression. Finally, A-769662 and CHIR-99021 act as indirect activators by influencing cellular energy homeostasis and the activity of AMP-activated protein kinase (AMPK) and glycogen synthase kinase-3 (GSK-3), respectively. These compounds can potentially impact CMV pp65 function through their effects on cellular metabolism and downstream signaling pathways. In conclusion, the CMV pp65 activators represent a diverse array of chemicals that intricately modulate the activity of CMV pp65, providing potential avenues for understanding the complex interactions between CMV and host cellular processes during infection.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor that may indirectly impact CMV pp65 activation. By inhibiting the p38 MAP kinase pathway, SB203580 can modulate downstream signaling cascades, potentially affecting cellular processes related to CMV pp65. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that may indirectly modulate CMV pp65 activation. By inhibiting the PI3K/Akt pathway, LY294002 can affect downstream signaling events, potentially influencing cellular processes related to CMV pp65. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an NF-κB inhibitor that could indirectly impact CMV pp65 activation. By inhibiting the NF-κB pathway, BAY 11-7082 may influence the transcriptional regulation of genes involved in cellular processes related to CMV pp65. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may indirectly modulate CMV pp65 activation. By inhibiting the JNK pathway, SP600125 can affect downstream signaling events, potentially influencing cellular processes related to CMV pp65. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that may indirectly impact CMV pp65 activation. By inhibiting the mTOR pathway, Rapamycin can influence cellular processes related to CMV pp65, potentially altering its activity and involvement in specific pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that could indirectly modulate CMV pp65 activation. By inhibiting the PI3K pathway, Wortmannin may impact downstream signaling events, potentially influencing cellular processes related to CMV pp65. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 is a histone deacetylase (HDAC) inhibitor that may indirectly influence CMV pp65 activation. By modulating the acetylation status of histones, SP2509 can impact gene expression and potentially affect cellular processes related to CMV pp65. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
This compound, also called JSH-23, is an inhibitor of nuclear factor-κB (NF-κB) translocation that may indirectly modulate CMV pp65 activation. By inhibiting NF-κB translocation to the nucleus, JSH-23 can influence the transcriptional regulation of genes involved in cellular processes related to CMV pp65. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $36.00 $110.00 $400.00 | ||
BIX 01294 is a G9a histone methyltransferase inhibitor that could indirectly impact CMV pp65 activation. By inhibiting G9a, BIX 01294 may modulate the methylation status of histones, potentially influencing gene expression and cellular processes related to CMV pp65. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A-769662 is an AMP-activated protein kinase (AMPK) activator that may indirectly influence CMV pp65 activation. By activating AMPK, A-769662 can impact cellular energy homeostasis and downstream signaling pathways, potentially affecting processes related to CMV pp65. | ||||||